On the Sidelines of the Battle for Caremark

John Snow, the CEO of the Nation’s largest prescription benefit manager, Medco, observed this week that his company stands to benefit from the Caremark merger no matter which suitor, CVS or Express Scripts, prevails. According to Reuters, Snow said that “We’ve been getting calls from retailers asking how they can stay aligned with us as the possibility of a CVS-Caremark combination blooms. I think that is nothing but good for us and our customers.” Although I have no idea whether this is a coincidental or related development, Medco’s common stock price rose almost 10% this week from $53.67 last Friday to $58.71 today.